Reduced progesterone levels explain the reduced risk of breast cancer in obese premenopausal women: a new hypothesis Mitch DowsettElizabeth Folkerd Review 21 November 2014 Pages: 1 - 4
HER2-family signalling mechanisms, clinical implications and targeting in breast cancer N. ElsterD. M. CollinsB. T. Hennessy Review 27 December 2014 Pages: 5 - 15
Stearidonic acid-enriched flax oil reduces the growth of human breast cancer in vitro and in vivo K. SubediH.-M. YuC. J. Field Preclinical study 23 November 2014 Pages: 17 - 29
Inherited predisposition to breast cancer among African American women Jane E. ChurpekTom WalshOlufunmilayo I. Olopade Preclinical study Open access 27 November 2014 Pages: 31 - 39
A genetic variant at 12p11 significantly modifies breast cancer risk in a genetically homogenous island population Terri Patricia McVeighUna Mary McVeighNicola Miller Preclinical study 05 December 2014 Pages: 41 - 47
Obesity-associated systemic interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 production Laura W. BowersAndrew J. BrennerLinda A. deGraffenried Preclinical study 05 December 2014 Pages: 49 - 57
Sphingosine kinase 1 contributes to leptin-induced STAT3 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer Heba AlshakerQi WangDmitri Pchejetski Preclinical Study 07 December 2014 Pages: 59 - 67
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer Jennifer R. BeanSarah R. HosfordTodd W. Miller Preclinical study 10 December 2014 Pages: 69 - 79
HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts Patricia de CremouxMathieu DalvaiDidier Decaudin Preclinical study 12 December 2014 Pages: 81 - 89
Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors Elizabeth S. YehMelissa A. AbtElizabeth G. Hill Preclinical Study Open access 17 December 2014 Pages: 91 - 98
In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer Yuqi JingMarcela Toro BejaranoJaime R. Merchan Preclinical study 18 December 2014 Pages: 99 - 108
Effects of the BEAT Cancer physical activity behavior change intervention on physical activity, aerobic fitness, and quality of life in breast cancer survivors: a multicenter randomized controlled trial Laura Q. RogersKerry S. CourneyaEdward McAuley Clinical trial 23 November 2014 Pages: 109 - 119
Expression profiling of circulating tumor cells in metastatic breast cancer Julie E. LangJanet H. ScottJohn W. Park Clinical trial 29 November 2014 Pages: 121 - 131
Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast Jing LiuYang YuXu-chen Cao Clinical trial 05 December 2014 Pages: 133 - 140
Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer Hans-Joachim LückKristina LübbeSibylle Loibl Clinical Trial 18 December 2014 Pages: 141 - 149
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer Sara TolaneyHoward BurrisIan Krop Clinical Trial 24 December 2014 Pages: 151 - 161
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study A. R. TanH. JohannesN. Wolmark Clinical trial 27 December 2014 Pages: 163 - 169
Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer Michael R. ClemensOleg A. GladkovAnne Keating Clinical trial Open access 30 December 2014 Pages: 171 - 179
Single-nucleotide polymorphisms in DNA bypass polymerase genes and association with breast cancer and breast cancer subtypes among African Americans and Whites Leila FamilyJeannette T. BensenAndrew F. Olshan Epidemiology 23 November 2014 Pages: 181 - 190
Incidence of breast cancer in a cohort of 5,135 transgender veterans George R. BrownKenneth T. Jones Epidemiology 27 November 2014 Pages: 191 - 198
Geographic access and age-related variation in chemotherapy use in elderly with metastatic breast cancer Shaowei WanSteven Jubelirer Epidemiology 04 December 2014 Pages: 199 - 209
Toward the breast screening balance sheet: cumulative risk of false positives for annual versus biennial mammograms commencing at age 40 or 50 Caleb J. WinchKerry A. ShermanJohn Boyages Epidemiology 05 December 2014 Pages: 211 - 221
Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry Eric RosenthalKelsey MoyesRichard J. Wenstrup Epidemiology 06 December 2014 Pages: 223 - 227
Reduced risk of axillary lymphatic spread in triple-negative breast cancer Emil Villiam Holm-RasmussenMaj-Britt JensenTove Filtenborg Tvedskov Epidemiology 09 December 2014 Pages: 229 - 236
Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: a study from a population-based screening program Xavier CastellsLaia DomingoMaría Sala Epidemiology Open access 13 December 2014 Pages: 237 - 244
Immunoassay and Nb2 lymphoma bioassay prolactin levels and mammographic density in premenopausal and postmenopausal women the Nurses’ Health Studies Megan S. RiceShelley S. TworogerRulla M. Tamimi Epidemiology 13 December 2014 Pages: 245 - 253
Pregnancy-associated breast cancer in women from Shanghai: risk and prognosis Kathrin Strasser-WeipplRitesh RamchandaniPaul E. Goss Epidemiology 14 December 2014 Pages: 255 - 261
No effect of scalp cooling on survival among women with breast cancer J. LemieuxL. ProvencherE. Maunsell Epidemiology 16 December 2014 Pages: 263 - 268
Fulvestrant and male breast cancer: a pooled analysis Flora ZagouriTheodoros N. SergentanisTheodora Psaltopoulou Epidemiology 18 December 2014 Pages: 269 - 275
Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis Naoki HayashiNaoki NiikuraHiroji Iwata Epidemiology 21 December 2014 Pages: 277 - 284
Greater absolute risk for all subtypes of breast cancer in the US than Malaysia Hisani N. HorneC. R. Beena DeviXiaohong R. Yang Epidemiology 24 December 2014 Pages: 285 - 291
Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications Katarzyna J. JerzakJessica CockburnAnita Bane Epidemiology 27 December 2014 Pages: 293 - 301
Confocal fluorescence microscopy for rapid evaluation of invasive tumor cellularity of inflammatory breast carcinoma core needle biopsies Jessica DobbsSavitri KrishnamurthyRebecca Richards-Kortum Brief Report Open access 23 November 2014 Pages: 303 - 310
Erratum to: Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer Ben P. HaynesGiuseppe VialeMitch Dowsett Erratum 26 November 2014 Pages: 311 - 311
Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies Chris TwelvesJavier CortesAhmad Awada Erratum 09 January 2015 Pages: 313 - 313